Bio-Techne announced new SARS-CoV-1/2 spike RBD LlaMABody recombinant antibody that blocks viral entry
On Aug. 11, 2020, Bio-Techne announced the release of the SARS-CoV-1/2 Spike RBD LlaMABody Recombinant Antibody, which binds…
-
-
Experimental COVID-19 vaccine prevented severe disease in mice
On Aug. 11, 2020, an experimental vaccine was reported to be effective at preventing pneumonia in mice infected…
-
Clinical trials of monoclonal antibodies to prevent COVID-19 began enrollment
On Aug. 10, 2020, two Phase 3, randomized, placebo-controlled, double-blind clinical trials testing whether experimental monoclonal antibodies (mAbs)…
-
Gilead submited New Drug Application to FDA for Veklury (Remdesivir) for treatment of COVID-19
On Aug. 10, 2020, Gilead Sciences announced that it had submitted a New Drug Application (NDA) to the…
-
OpGen began co-marketing COVID-19 antibody test kit
On Aug. 9, 2020, OpGen announced that it had commenced marketing and promotion, on a non-exclusive basis, of…
-
Scientists revealed structural details of spike protein used in leading COVID-19 vaccine
On Aug. 7, 2020, scientists at Scripps Research announced they had obtained high-resolution, atomic-scale details of the structure…
-
Novavax and Takeda announced collaboration for Novavax COVID-19 vaccine candidate in Japan
On Aug. 7, 2020, Novavax and Takeda Pharmaceutical announced a partnership for the development, manufacturing and commercialization of…
-
FDA approved two emergency INDs for COVID-19 outpatient therapy
On Aug. 6, 2020, Organicell Regenerative Medicine, a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies,…
-
HKUMed discovered that acute SARS-CoV-2 infection impairs human immune defences
On Aug. 6, 2020, researchers at the AIDS Institute, Department of Microbiology and State Key Laboratory of Emerging…
-
Novavax signed COVID-19 vaccine supply deal with India’s Serum Institute
On Aug. 6, 2020, Novavax announced it had entered a supply and license agreement with the Serum Institute…
-
NIH began clinical trial testing remdesivir plus interferon beta-1a for COVID-19 treatment
On Aug. 5, 2020, a randomized, controlled clinical trial evaluating the safety and efficacy of a treatment regimen…
-
NIH harnessed AI for COVID-19 diagnosis, treatment, and monitoring
On Aug. 5, 2020, the National Institutes of Health (NIH) announced it had launched the Medical Imaging and…
-
NIH-Moderna investigational COVID-19 vaccine showed promise in mouse studies
On Aug. 5, 2020, the National Institute of Allergy and Infectious Diseases (NIAID) announced that the investigational vaccine…
-
Tecan’s automation technology leveraged by Thermo Fisher to scale-up COVID-19 testing globally
On Aug. 5, 2020, the Tecan Group and Thermo Fisher Scientific announced a collaboration to enable scaled-up COVID-19…
-
BioNTech and Fosun Pharma announced start of clinical trial of mRNA-based COVID-19 vaccine candidate in China
On Aug. 5, 2020, BioNTech and Shanghai Fosun Pharmaceutical announced that the first 72 participants had been dosed…
-
Johnson & Johnson announces agreement with US Government for 100 million doses of investigational COVID-19 vaccine
On Aug. 5, 2020, Johnson & Johnson announced a $1 billion agreement with the U.S. government for the…
-
Pfizer and BioNTech to supply Canada with their BNT162 mRNA- based vaccine candidate
On Aug. 5, 2020, Pfizer Canada and BioNTech SE today announced an agreement with the Government of Canada…
-
AXIM Biotechnologies applied for FDA Emergency Use Approval for high throughput, neutralizing antibody diagnostic test for COVID-19
On Aug. 5, 2020, AXIM Biotechnologies announced the development, patent filing and Emergency Use Approval (EUA) filing of…
-
VBI Vaccines awarded up to CAD$56 million contribution from Canadian Government to accelerate Coronavirus vaccine development
On Aug. 5, 2020, Variation Biotechnologies, an Ottawa-based subsidiary of VBI Vaccines, announced that it had been awarded…
-
NIH launched clinical trial to test antibody treatment in hospitalized COVID-19 patients
On Aug. 4, 2020, the National Institutes of Health (NIH) announced that patients admitted with COVID-19 at select…
-
HKUMed researchers first discovered SARS-CoV-2 infects human neural progenitor cells and brain organoids
On Aug. 4, 2020, researchers at The University of Hong Kong (HKUMed) collaborated with researchers at the Institute…
-
Innovation Pharma and US Regional Biocontainment Laboratory updated brilacidin anti-SARS-CoV-2 in vitro testing
On Aug. 4, 2020, Innovation Pharma reported receiving an update from a U.S. Regional Biocontainment Laboratory (RBL) based…
-
Novavax announced positive phase 1 data for its COVID-19 vaccine candidate
On Aug. 4, 2020, Novavax announced Phase 1 data from its Phase 1/2 randomized, observer-blinded, placebo-controlled trial of…
-
Cocrystal Pharma announced publication of positive data demonstrating potent in vitro inhibition against Coronavirus
On Aug. 4, 2020, Cocrystal Pharma announced the publication of preclinical animal studies of coronavirus antiviral compounds in…
-
Oxford University and ZOE partnered on COVID-19 treatment trials
On Aug. 3, 2020, the University of Oxford and the COVID Symptom Study joined forces to widen access…
-
La Jolla Institute for Immunology received $1 million from GHR Foundation in support of COVID-19 research
On Aug. 3, 2020, the La Jolla Institute for Immunology (LJI) announced a $1 million gift from GHR…
-
Lilly initiated phase 3 trial of LY-CoV555 for prevention of COVID-19 at Long-term care facilities in partnership with NIAID
On Aug. 3, 2020, Eli Lilly announced the initiation of BLAZE-2, a phase 3 trial studying LY-CoV555 for…
-
Bio-Techne and Kantaro Biosciences to launch a quantitative research use only COVID-19 serology test
On Aug. 3, 2020, Bio-Techne and the Mount Sinai Health System in New York, through its commercial affiliate…
-
Pathnova Laboratories announced partnership to commercialize Todos Medicals COVID-19 and breast cancer tests in Singapore
On Aug. 3, 2020, Todos Medical announced a partnership with PATHNOVA, a Singapore-based clinical laboratory, for the Company’s…
-
Atossa Therapeutics received approval to open clinical study of AT-301 nasal spray being developed to treat COVID-19
On Aug. 3, 2020, Atossa Therapeutics announced that it had received approval from the ethics committee to open…
